Funding

Boston-Based Elucid Raises $55M in Series D Funding

Sep 3, 2026 | By Devin Jacobs

SUMMARY

Elucid raised $55M in Series D funding.
The funding will support AI research and expansion.
Elucid develops AI-powered cardiovascular imaging software.

Elucid, a Boston, MA-based provider of AI-powered, clinically validated software to advance precision diagnosis and treatment of cardiovascular disease, has raised $55 million in a Series D funding round, bringing the total amount to approximately $185 million.

The round saw backers IAG Capital Partners, Elevage Medical Technologies, and an undisclosed strategic investor.

The company will use the new capital to expand commercially, advance AI research, and support clinical studies.

Funding Snapshot

Metric	Details
Fundraise Amount	$55 Million
Total Funding	Approximately $185 Million
Valuation	Not disclosed
Company	Elucid
Sector	HealthTech / Medical Technology
Headquarters	Boston, Massachusetts, US

RECOMMENDED FOR YOU

Funding

Funding Wrap of the Week | American Startups Funding Roundup | May 5 – May 10

Devin Jacobs

May 11, 2024

Funding

[Funding News] Axiad Raises $25 Million Private Equity Funding

Team SR

Jul 31, 2024

Startup News

Reed Hastings to step down from Netflix board

Devin Jacobs

Apr 17, 2026

About Elucid

Founded in 2013 Elucid develops AI-powered cardiovascular imaging technology designed to help physician's identify and assess atherosclerosis more precisely. Their platform, including the FDA-cleared Plaque-IQ image analysis software, allows physicians to quantify plaque composition and stratify at risk patients.

Core offerings include:

Plaque-IQ image analysis software
BioIntegrated FFR-CT
AI-powered cardiovascular imaging
Personalized cardiovascular risk assessment

Core Technologies / Products / Services

Capability/Product	Application/Use Case
Plaque-IQ	Quantifies high-risk plaque and plaque composition
FFR-CT	Provides non-invasive assessment of coronary blood flow
AI Image Analysis	Converts CT angiography into detailed disease insights
Clinical Decision Platform	Supports personalized treatment strategies

Leadership Comments

“Analogous to oncology's shift from population-based, one-size treatment, Elucid is applying AI to integrate anatomy, biology, and physiology to bring personalized treatment to coronary artery disease management. Physician feedback indicating that our current platform can uniquely lead to better care decisions fuels our mission to predict and personalize the prevention of heart attacks and strokes,” said Kelly Huang, PhD, chief executive officer of Elucid.